Q2 EPS Estimates for Prime Medicine Lifted by HC Wainwright

Prime Medicine, Inc. (NASDAQ:PRME) – Analysts at HC Wainwright boosted their Q2 2026 earnings estimates for Prime Medicine in a research note issued on Monday, June 29th. HC Wainwright analyst A. He now forecasts that the company will post earnings of ($0.28) per share for the quarter, up from their previous forecast of ($0.29). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Prime Medicine’s Q3 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.17) EPS, Q1 2027 earnings at ($0.22) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.23) EPS, Q4 2027 earnings at ($0.23) EPS and FY2027 earnings at ($0.90) EPS.

A number of other research firms have also recently commented on PRME. Citigroup reissued a “market outperform” rating on shares of Prime Medicine in a research note on Monday, June 22nd. Oppenheimer assumed coverage on Prime Medicine in a report on Thursday, March 12th. They issued an “outperform” rating and a $11.00 price objective for the company. Wall Street Zen lowered Prime Medicine from a “sell” rating to a “strong sell” rating in a research report on Wednesday, May 13th. New Street Research set a $8.00 price objective on Prime Medicine in a research report on Monday. Finally, The Goldman Sachs Group set a $6.00 price objective on Prime Medicine in a report on Monday, June 22nd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.53.

Prime Medicine Stock Performance

NASDAQ PRME opened at $3.69 on Wednesday. Prime Medicine has a 52-week low of $2.28 and a 52-week high of $6.94. The company has a fifty day moving average of $3.25 and a 200-day moving average of $3.57. The company has a market capitalization of $666.49 million, a P/E ratio of -3.00 and a beta of 2.31.

Prime Medicine (NASDAQ:PRME) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The company had revenue of $0.86 million during the quarter. Prime Medicine had a negative return on equity of 188.82% and a negative net margin of 4,917.55%.

Hedge Funds Weigh In On Prime Medicine

Large investors have recently added to or reduced their stakes in the business. Shelton Wealth Management LLC boosted its position in Prime Medicine by 15.8% during the fourth quarter. Shelton Wealth Management LLC now owns 20,066 shares of the company’s stock valued at $70,000 after buying an additional 2,734 shares during the period. Sterling Investment Advisors Ltd. increased its holdings in shares of Prime Medicine by 34.0% in the fourth quarter. Sterling Investment Advisors Ltd. now owns 13,400 shares of the company’s stock worth $46,000 after buying an additional 3,400 shares during the period. Squarepoint Ops LLC lifted its stake in shares of Prime Medicine by 10.5% in the 3rd quarter. Squarepoint Ops LLC now owns 39,601 shares of the company’s stock valued at $219,000 after acquiring an additional 3,775 shares during the last quarter. Royal Bank of Canada lifted its stake in shares of Prime Medicine by 89.3% in the 1st quarter. Royal Bank of Canada now owns 9,254 shares of the company’s stock valued at $32,000 after acquiring an additional 4,365 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in Prime Medicine by 16.5% during the 4th quarter. The Manufacturers Life Insurance Company now owns 31,602 shares of the company’s stock valued at $110,000 after acquiring an additional 4,470 shares during the period. Hedge funds and other institutional investors own 70.37% of the company’s stock.

Prime Medicine Company Profile

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.